Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective

• Published in: Dermatology Research and Practice
• Main Author: Johar A.; Thevarajah S.; Heng A.; Chan L.C.; Ch'Ng C.C.; Mohd Safdar N.A.; Muniandy P.; Taib T.; Tan W.C.; Tey K.E.
• Format: Review
• Language: English
• Published: Hindawi Limited 2019
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066299771&doi=10.1155%2f2019%2f8923168&partnerID=40&md5=dbbd994246633a9cab4604beaa6cafd1

Psoriasis is a chronic inflammatory skin disease affecting nearly 10% of dermatologic patients in Malaysia. Treatment options include topical agents and phototherapy as well as nonbiologic and biologic systemic therapy. Mild psoriasis can often be managed with topical agents. However, managing moderate to severe psoriasis is more challenging and may require systemic treatment with nonbiologics or biologics. Despite the availability of several biologics, there are many unmet clinical needs, which may be addressed by secukinumab, an IL-17A inhibitor. This position statement is based on an expert panel discussion and is intended to provide dermatologists an overview of existing options as well as to provide a better understanding of secukinumab and how it can be integrated into current practice. During the discussion, panel members examined current approaches and the role of secukinumab in plaque psoriasis management. Panel members estimated that up to 30% of patients have moderate to severe psoriasis but only 1-2% receive biologics. Highlights from the discussion were that (i) the threshold for biologic use should be lower, in line with international guidelines; (ii) studies have shown that secukinumab has several advantages over other biologics which are greater efficacy, sustained efficacy over time, rapid onset of action, and early evidence of possible disease-modifying potential; and (iii) ideal candidates for secukinumab are all patients of moderate to severe psoriasis, including those with history of treatment failure, difficult-to-treat patterns of psoriasis (nail, scalp, and palmoplantar psoriasis), psoriatic arthritis, and comorbidities and those aiming for clear skin. Panel members recommend that secukinumab be considered first line option among biologic therapies. © 2019 Asmah Johar et al.